Areas of improvement in the medical care of SMA: evidence from a nationwide patient registry in Germany
- PMID: 36810103
- PMCID: PMC9945617
- DOI: 10.1186/s13023-023-02639-z
Areas of improvement in the medical care of SMA: evidence from a nationwide patient registry in Germany
Abstract
Background: Management and treatment of spinal muscular atrophy (SMA) has changed in recent years due to the introduction of novel transformative and potentially curative therapies resulting in the emergence of new disease phenotypes. Yet, little is known about the uptake and impact of these therapies in real-world clinical practice. The objective of this study was to describe current motor function, need of assistive devices, and therapeutic and supportive interventions provided by the healthcare system, as well as the socioeconomic situation of children and adults with different SMA phenotypes in Germany. We conducted a cross-sectional, observational study of German patients with genetically confirmed SMA identified and recruited via a nationwide SMA patient registry ( www.sma-register.de ) within the TREAT-NMD network. Study data was recorded directly from patient-caregiver pairs through a study questionnaire administered online via a dedicated study website.
Results: The final study cohort consisted of 107 patients with SMA. Of these, 24 were children and 83 adults. In total, about 78% of all participants were taking medication for SMA (predominantly nusinersen and risdiplam). All children with SMA1 were able to sit and 27% of children with SMA2 were able to stand or walk. Impaired upper limb function, scoliosis and bulbar dysfunction were observed more frequently in patients with reduced lower limb performance. Physiotherapy, occupational therapy, and speech therapy, as well as the use of cough assists were less common than indicated by care guidelines. Family planning and educational and employment status appear to be related to motor skill impairment.
Conclusions: We show that the natural history of disease has changed in Germany following improvements in SMA care and the introduction of novel therapies. Yet, a non-trivial proportion of patients remain untreated. We also identified considerable limitations in rehabilitation and respiratory care, as well as low labour-market participation among adults with SMA, calling for action to improve the current situation.
Keywords: (8/10): spinal muscular atrophy; Bulbar function; Medical care; Motor function; Non-invasive ventilation; Nusinersen; Rehabilitation; Risdiplam.
© 2023. The Author(s).
Conflict of interest statement
Dr. Marina Flotats-Bastardas has received consultant fees from Roche and Biogen. Dr. Landfeldt and Ms. Abner are employees of IQVIA, a contract research organization. Dr. Maggie C. Walter has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, Roche, Santhera, Sarepta, Pharnext, PTC Therapeutics, Ultragenyx, Wave Sciences, received funding for Travel or Speaker Honoraria from Avexis, Biogen, PTC Therapeutics, Ultragenyx, Santhera, Sarepta, and worked as an ad-hoc consultant for AskBio, Audentes Therapeutics, Avexis, Biogen Pharma GmbH, Fulcrum Therapeutics, GLG Consult, Guidepoint Global, Gruenenthal Pharma, Novartis, Pharnext, PTC Therapeutics, Roche. Simone Thiele has received financial support for advisory services from PTC. The other authors declare that there is no conflict of interest.
Similar articles
-
Health-related quality of life of adults with spinal muscular atrophy: insights from a nationwide patient registry in Germany.Qual Life Res. 2024 Jul;33(7):1949-1959. doi: 10.1007/s11136-024-03665-5. Epub 2024 May 16. Qual Life Res. 2024. PMID: 38753126
-
Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.Orphanet J Rare Dis. 2022 Jul 19;17(1):276. doi: 10.1186/s13023-022-02420-8. Orphanet J Rare Dis. 2022. PMID: 35854272 Free PMC article.
-
Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy.Orphanet J Rare Dis. 2021 Mar 24;16(1):150. doi: 10.1186/s13023-021-01771-y. Orphanet J Rare Dis. 2021. PMID: 33761963 Free PMC article.
-
Drug treatment for spinal muscular atrophy type I.Cochrane Database Syst Rev. 2019 Dec 11;12(12):CD006281. doi: 10.1002/14651858.CD006281.pub5. Cochrane Database Syst Rev. 2019. PMID: 31825542 Free PMC article.
-
Nusinersen treatment of spinal muscular atrophy - a systematic review.Dan Med J. 2020 Aug 7;67(9):A02200100. Dan Med J. 2020. PMID: 32800069
Cited by
-
Agreement Between Child Self- and Parent Proxy-Reports of Health-Related Quality of Life in Spinal Muscular Atrophy: Preliminary Insights from a Nationwide Patient Registry in Germany.Patient Relat Outcome Meas. 2025 Jun 27;16:93-103. doi: 10.2147/PROM.S517362. eCollection 2025. Patient Relat Outcome Meas. 2025. PMID: 40600202 Free PMC article.
-
A contemporary analysis of the Australian clinical and genetic landscape of spinal muscular atrophy: a registry based study.Lancet Reg Health West Pac. 2024 Nov 6;53:101237. doi: 10.1016/j.lanwpc.2024.101237. eCollection 2024 Dec. Lancet Reg Health West Pac. 2024. PMID: 39559164 Free PMC article.
-
Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.J Neurol. 2024 Aug;271(8):5378-5391. doi: 10.1007/s00415-024-12442-w. Epub 2024 Jul 2. J Neurol. 2024. PMID: 38954034 Free PMC article.
-
5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2.J Neurol. 2024 May;271(5):2787-2797. doi: 10.1007/s00415-024-12188-5. Epub 2024 Feb 27. J Neurol. 2024. PMID: 38409538 Free PMC article.
-
Health-related quality of life of adults with spinal muscular atrophy: insights from a nationwide patient registry in Germany.Qual Life Res. 2024 Jul;33(7):1949-1959. doi: 10.1007/s11136-024-03665-5. Epub 2024 May 16. Qual Life Res. 2024. PMID: 38753126
References
-
- Baranello G, Servais L, Day J, Deconinck N, Mercuri E, Klein A. P.353FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with type 1 spinal muscular atrophy. Neuromuscu Disord. 2019;29:S184. doi: 10.1016/j.nmd.2019.06.515. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical